9 July 2019 - NICE has recommended the use of Alynylam’s Onpattro (patisiran), after issuing a preliminary ‘no’, back in December 2018.

The treatment is for a progressive, life-threatening disease called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), which up until now was an area of significant unmet need in England.

The drug will now provide eligible patients suffering from the disease with a treatment option that addresses its underlying cause by reducing the production of an abnormal protein that damages nerves and organs across the body.

Read Pharma Times article